| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
Tumor and adjacent normal tissue biopsy specimens were obtained before/after treatment from 34 patients(124 samples) treated with a uniform CRT protocol. We analyzed genomewide DNA methylation of 12 non-treated test samples(T and matched ADJ : 6 each) by methylated CpG island amplification and microarray(MCAM) method, and selected candidate genes that were highly methylated in T compared to ADJ. CYP26C1 was selected by unsupervised hierarchical clustering after MCAM in test samples, and was also ranked in the top 5 of both molecular & cellular function networks as a drug metabolism category. CYP26C1 DNA methylation was significantly higher in T than ADJ in both test and validation samples. CYP26C1 has a CpG island in promoter area, which is highly methylated in T of ESCC patients.
|
